ACUTRIM II, DEXATRIM-15 BIOAVAILABILITY TESTS REQUIRED
• By The Pink Sheet
ACUTRIM II, DEXATRIM-15 BIOAVAILABILITY TESTS REQUIRED in order for Ciba-Geigy and Thompson Medical to continue shipping their respective products, U.S. District Judge Vincent Broderick ruled in a Jan. 2 order. Broderick said Thompson Medical and Ciga-Geigy are "enjoined from shipping, or causing to be shipped, any further packages of ]Dexatrim-15 or Acutrim II, respectively[ until ]they have[ conducted appropriate tests sufficient to conform with the opinions of this court dated Jan. 30, 1984 and Dec. 19, 1985 rendered in Ciba-Geigy v. Thompson Medical." Thompson Medical said such tests are bioavailability studies that would show that phenylpropanolamine products maintain concentrations of 60 nanograms per milliliter of blood for the claimed hours of effectiveness, i.e., 15 hours for Dexatrim-15 and 17 hours for Acutrim II. Ciba-Geigy said it will conduct an additional study to support its duration claim for Acutrim II. The company's Acutrim product has a 16-hour claim of action. Dexatrim Extra Strength and Regular Dexatrim do not have a specified length of action. Ciba-Geigy filed suit against Thompson Medical in New York Federal Court Sept. 6 protesting Thompson's claims of 15-hour duration of action for Dexatrim-15 ("The Pink Sheet" Sept. 16, T&G-10). Ciba-Geigy maintained Thompson's bioavailability study shows that the product's duration is less than 12 hours. The court also ruled that both firms must let the other know if they decide to market their two products in a redesigned package and under a different duration claim. Each firm must submit the redesigned packaging and claim of support to the other company, which in turn has 10 days to accept or dispute the redesigned package. A firm must provide a written statement of reasons if it rejects the package and has five business days to institute a court proceeding challenging the proposed remarketing. In addition, if either firm decides to market a product (other than those in existing inventories) with the respective 15-hour or 17-hour claim, the firm shall submit to the other "the protocol, results, analyses and underlying data for all tests evidencing the duration of such product," along with the proposed packaging of the product. The court further enjoined Ciba-Geigy from "making any express or implied claims of therapeutic advantage or superiority over Extra-Strength Dexatrim or other phenylpropanolamine appetite suppressants in any packaging, labeling, advertising, or promotional materials for Acutrim or Acutrim II" unless and until the company has "at least one adequate and well-controlled comparative clinical study which demonstrates such therapeutic advantage or superiority." Broderick asserted that "in the event that either party markets any phenylpropanolamine appetite suppressant with a duration claim -- including but not limited to a claim of a specific number of hours of duration -- all packaging, advertising or promotional material containing such a claim shall explicitly state that said claim relates solely to blood levels." He added that the requirement "applies to all currently marketed and future phenylpropanolamine products" of Ciba-Geigy and Thompson Medical and their affiliates. Thompson Medical stated in a Jan. 3 press release that "although no final decision has been made," the firm "probably will reformulate Dexatrim-15 to confirm with the court's ruling."
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.
It appears that the European Medicines Agency is making progress on its re-examination of Eli Lilly’s Alzheimer’s disease drug Kisunla, following an initial rejection in March based on safety concerns.
Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.